title: Myo-inositol vs. D-chiro inositol in PCOS treatment.
abstract: OBJECTIVE
  Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women in fertile age. It is an endocrine and metabolic disorder characterized by oligo-anovulation, hyperandrogenism and insulin-resistance. Various therapeutic approaches have been attempted in PCOS, including diet and the use of pharmacological agents such as oral contraceptives (OCs) or anti-androgens. Recently, the introduction of inositol in the treatment plan has proved to be as reasonable as useful in countering the endocrine-metabolic disorders of this syndrome.
  
  
  METHODS
  The aim of our study was to compare the clinical, endocrine and metabolic response after 6 months of therapy in 137 PCOS women characterized by oligomenorrhea and/or acne and/or mild hirsutism and insulin-resistance. The patients were treated with myo-inositol or with D-chiro-inositol or with placebo.
  
  
  RESULTS
  Our study showed that both myo-inositol (MI-PG) and D-chiro inositol (DCI-PG) treatments are able to significantly improve the regularity of the menstrual cycle, the Acne Score, the endocrine and metabolic parameters and the insulin-resistence in young, overweight, PCOS patients.
  
  
  CONCLUSIONS
  Definitely, we assumed that both treatments with myo-inositol and with D-chiro inositol could be proposed as a potential valid therapeutic approach for the treatment of patients with PCOS. Additionally, further examination and for a longer period of treatment are needed.
authors: Institute of Obstetric and Gynecological Pathology, Santo Bambino Hospital - clara.formuso@gmail.com.
authors: C
authors: C
authors: Formuso
authors: M
authors: M
authors: Stracquadanio
authors: L
authors: L
authors: Ciotta
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy / Q000209:etiology; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006628:Hirsutism / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007294:Inositol / Q000008:administration & dosage / Q000627:therapeutic use*; D007333:Insulin Resistance; D008597:Menstrual Cycle / Q000187:drug effects*; D009839:Oligomenorrhea / Q000188:drug therapy / Q000209:etiology; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007294:Inositol